¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Mineralocorticoid Excess Syndrome, Apparent"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® mineralocorticoid ÇÑ±Û ¿°·ùÄÚ¸£Æ¼ÄÚÀ̵å, ±¤¹°ÄÚ¸£ÄÚÀ̵å
¼³¸í   
  ºÎ½Å°ÑÁú¿¡¼­ ³ª¿À´Â È£¸£¸óÁßÀÇ Çϳª. À̠ȣ¸£¸óÀº »ç¶÷ÀÇ ±¤¿°(¶Ç´Â ÀüÇØÁú: mineral salts, or electrolytes)ÀÇ ¾çÀ» Á¶ÀýÇϴ °¡Àå Áß¿äÇÑ ÀÎÀÚ´Ù. À̵éÀº Ã¼³»¿¡ Á¸ÀçÇϴ ¹°°ú À̿¾çÀ» Á¶ÀýÇÔÀ¸·Î½á, À̸¥¹Ù Àû´çÇѠü³»È¯°æÀ» ¸¸µé¾î Áִ °ÍÀÌ´Ù. ÀÌÁß °¡Àå Áß¿äÇѠȣ¸£¸óÀº ¾Ëµµ½ºÅ×·ÐÀ¸·Î ±â´ÉÀº, ÄáÆÏ¿¡¼­ ³ªÆ®·ýÀÇ Èí¼ö¸¦ Áõ°¡½Ã۰í, Ä®·ýÀÇ ¹è¼³À» ÃËÁøÇÔÀ¸½á Ã¼³» ¼öºÐÀÇ ¾çÀ» Á¶ÀýÇÑ´Ù.
¿µ¹® testicular feminization syndrome ÇÑ±Û °íȯ¿©¼ºÈ­ÁõÈıº
¼³¸í   
  ÀÌÂ÷¼ºÀåÀ» Æ÷ÇÔÇÏ¿©, ¿Ü¼º±âÀÇ ¹ßÀ°Àº ¿©¼ºÀÌÁö¸¸ °íȯÀÌ Á¸ÀçÇϰí, Àڱðú ÀڱðüÀÌ °áÇ̵Ǿî Àִ ³²¼º °ÅÁþ³²³àÇѸöÁõÀÇ ±Ø´ÜÀû ÇüÅÂÀÌ´Ù. À̰ÍÀº Å×½ºÅ佺Å×·ÐÀÇ ÀÛ¿ë¿¡ ´ëÇÑ ¸»´Ü±â°üÀÇ ÀúÇ׿¡ ±âÀÎÇÑ´Ù.
  
  
¿µ¹® irritable bowel syndrome ÇÑ±Û °ú¹Î¼º´ëÀåÁõÈıº
¼³¸í   
  ¹èº¯Àå¾Ö, º¹Åë, º¹ºÎÆØ¸¸ µîÀÇ Áõ»óÀÌ ÀÖÀ¸³ª ±âÁúÀûÀΠº´º¯ÀÌ ¾øÀ½ÀÌ È®ÀεȠ¿¹¸¦ ÃѸÁ¶óÇÑ ÀÓ»ó ÁõÈıºÀÌ´Ù. °¡Àå ÈçÇÑ ¼ÒÈ­±â ÁúȯÀ̸ç(Àü¼ÒÈ­±â È¯ÀÚÀÇ 70~80%) °¡Àå ÈçÇÑ Áúº´(Àüü Àα¸ÀÇ ¾à 20%)ÀÌ´Ù. ¿©¼ºÀÌ ³²¼º¿¡ ºñÇØ 2¹è Á¤µµ ¸¹ÀÌ ¹ß»ýÇϸç 30´ë ¹× 40´ë¿¡¼­ È£¹ßÇÏ°í ¼±Áø °ø¾÷±¹¿¡¼­ ¸¹ÀÌ ¹ß»ýÇÑ´Ù. Áø´ÜÀ» À§Çؼ­´Â º´·Â Ã»Ãë°¡ °¡Àå Áß¿äÇ졒ʡ¢Á¾ °Ë»ç·Î¼­ ±âÁúº´À» Á¦¿ÜÇØ¾ß ÇÑ´Ù. Ä¡·á·Î´Â ¾ÈÁ¤¿ä¹ý(Á¤½Å°úÀû ¸é´ã ¹× ½É¸®¿ä¹ý, ½Å°æ¾ÈÁ¤Á¦), ½Ä»ç¿ä¹ý(°í¼¶À¯Áú À½½Ä ¼·Ãë, Àڱؼº À½½Ä ÇÇÇϱâ), ¾à¹° ¿ä¹ý(âÀÚ°æ·Ã ÁøÁ¤Á¦, º¯ºñ ¿ÏÈ­Á¦, Áö»çÁ¦) µîÀ» »ç¿ëÇÑ´Ù.
¿µ¹® withdrawal syndrome ÇÑ±Û ±Ý´ÜÁõÈıÙ
¼³¸í   
  ¾ËÄÚ¿Ã, ¸¶¾à, ¹ÙºñÅõ¸£»ê°è ÃÖ¸é¾à µîÀÇ ¾à¹°À» Àå±â°£ º¹¿ëÇÏ¿© ¾à¹°ÀÌ ¾øÀ̴ °ßµô ¼ö ¾ø°ÔµÈ µÚ, ±× ¾à¹°À» ÁßÁöÇÑ °æ¿ì¿¡ ³ªÅ¸³ª´Â, °íÅëÀÌ ¼ö¹ÝµÇ´Â ½ÅüÀû Áõ»óÀ» ¸»ÇÑ´Ù. ¿¬¼Ó º¹¿ëÀÇ ±â°£¿¡ µû¶ó Áõ»óÀÌ ¹«°Å¿öÁø´Ù. Åë»óÀûÀ¸·Î ±¸Åä, ¼³»ç, Ç÷¾Ð»ó½Â, ºü¸¥¸Æ, ¶¡³², È¥¼ö µîÀÇ Áõ»óÀÌ ³ªÅ¸³­´Ù.
  
  
¿µ¹® organic brain syndrome ÇÑ±Û ±âÁúÀû ³úÁõÈıº
¼³¸í   
  ³úÀÇ ±âÁúÀûÀÎ(organic-:ÀÌ ¸»Àº ±â´ÉÀûÀÎ(functional)¿¡ ¹ÝÇϴ ¸»·Î½á) ¸ðµç °Ë»ç¸¦ ½ÃÇàÇϸ頾 ÀÌ»óÀ» ¹ß°ßÇÒ ¼ö Àִٴ ¶æÀÌ´Ù. ¹Ù²Ù¾î ¸»Çϸé, ±â´ÉÀûÀΠÀ̻󿡠ÀÇÇÑ ³úÁõÈıºÀº ¾î¶°ÇÑ °Ë»ç·Îµµ ÀÌ»óÀ» ¹ß°ßÇÒ ¼ö ¾øÀ¸³ª ºÐ¸íÈ÷ È¯ÀÚ¿¡°Ô ÀÌ»óÁõ»óÀÌ ³ªÅ¸³µÀ» ¶§ À̸¦ ¹­¾î¼­ ¸»ÇÑ´Ù. À̻󿡠ÀÇÇØ ½Å°æÇÐÀûÀΠÀÌ»óÀ» ³ªÅ¸³»´Â ÀÏ·ÃÀÇ º´ÀûÇö»óÀ» ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ÀÌ º´Àº ÈçÈ÷ º¸¾Æ ¸¶Ä¡ Á¤½Åº´È¯ÀÚó·³ ¸»À» È¾¼³¼ö¼³Çϰí, ¾Ë¾ÆµéÀ» ¼ö ¾ø´Â ¸»À» Çϸç, ¶§·Î´Â ´Ù¸¥ »ç¶÷¿¡°Ô °ø°ÝÀûÀΠ¼ºÇâÀ» ³ªÅ¸³»±âµµ ÇÑ´Ù. ±×¸®°í ´Ù¸¥ »ç¶÷°ú µµÀúÈ÷ ±³·ù¸¦ ÇÒ ¼ö ¾ø´Â Á¤¼­¸¦ ³ªÅ¸³»±âµµ ÇÑ´Ù. ±×·¯³ª, ÀÌ º´ÀÌ ´Ù¸¥ Á¤½Åº´°ú ±¸º°µÇ´Â Æ¯Â¡ÀûÀΠÁõ»óÀº ¸ÕÀú, ÀǽÄÀǠȥŹÀÌ µ¿¹ÝµÇ´Â °æ¿ì°¡ ¸¹°í, ¶ÇÇÑ ±× Áõ»óÀÇ Á¤µµ°¡ º¯ÇѴٴ °ÍÀÌ´Ù. Áï, ¾ÆÄ§¿¡´Â Á¤»óÀûÀΠÇൿÀ» ÇÏ´Ù°¡ ¿ÀÈİ¡ µÇ¸é, ÀǽÄÀÌ Èå·ÁÁö¸é¼­ ¸»À» È¾¼³¼ö¼³ÇÑ´Ù¸é, À̴ ±âÁú¼º³úÁõÈıºÀÏ °¡´É¼ºÀÌ ³ô´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • mineralocorticoid
    ±¤¹°ºÎ½Å°ÑÁúÈ£¸£¸ó, ±¤¹°ÄÚ¸£Æ¼ÄÚÀ̵å
  • apparent death
    °¡»ç, °Ñº¸±â»ç¸Á
  • apparent density
    °Ñº¸±â¹Ðµµ
  • apparent diffusion coefficient
    °Ñº¸±âÈ®»ê°è¼ö
  • apparent infection
    Áõ»ó°¨¿°
  • apparent movement
    ½Ã¿îµ¿
  • apparent weight
    °Ñº¸±âÁß·®
  • antibody excess
    Ç×ü°úÀ×
  • antibody excess zone
    Ç×ü°úÀ×±¸¿ª
  • antigen excess
    Ç׿ø°úÀ×
  • antigen excess zone
    Ç׿ø°úÀ×±¸¿ª
  • accommodative excess
    Á¶Àý°ú´Ù
  • base excess
    ¿°±â°úÀ×
  • convergence excess
    ´«¸ðÀ½°ú´Ù
  • divergence excess
    ´«¹ú¸²°ú´Ù, °³»ê°ú´Ù
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • apparent death
    °¡»ç
  • excess
    °ú´Ù, °úÀ×
  • antigen excess
    Ç׿ø°úÀ×
  • acquired immunodeficiency syndrome
    (¢¡AIDS) ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
  • syndrome of inappropriate antidiuretic hormone
    Ç×ÀÌ´¢È£¸£¸óºÎÀûÀýºÐºñÁõÈıº
  • syndrome
    ÁõÈıº
  • adrenogenital syndrome
    ºÎ½Å¼º±âÁõÈıº
  • afferent loop syndrome
    µéâÀÚÁõÈıº
  • Alport syndrome
    ¾ËÆ÷Æ®ÁõÈıº
  • Asherman's syndrome
    (¢¡ intrauterine synechia) ¾Æ¼Å¸¸ÁõÈıº
  • carpal tunnel syndrome
    ¼Õ¸ñ±¼ÁõÈıº, ¼ö±Ù°üÁõÈıº
  • cauda equina syndrome
    ¸»ÃÑÁõÈıº, ¸¶¹ÌÁõÈıº
  • compartment syndrome
    ±¸È¹ÁõÈıº
  • contact urticaria syndrome
    Á¢Ã˵ε巯±âÁõÈıº
  • cubital tunnel syndrome
    ÆÈ²ß±¼ÁõÈıº
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • mineralocorticoid
    ±¤¹°ºÎ½Å°ÑÁúÈ£¸£¸ó
  • apparent death
    °¡»ç
  • apparent density
    °Ñº¸±â¹Ðµµ
  • apparent infection
    Áõ»ó°¨¿°
  • apparent movement
    ½Ã¿îµ¿
  • apparent strabismus
    ¿Ü°üÀû»ç½Ã
  • apparent viscosity
    °Ñº¸±âÁ¡¼º
  • apparent weight
    °Ñº¸±âÁß·®
  • apparent diffusion coefficient
    °Ñº¸±âÈ®»ê°è¼ö
  • accommodative excess
    Á¶Àý°ú´Ù
  • antibody excess
    Ç×ü°úÀ×
  • antibody excess zone
    Ç×ü°úÀ×±¸¿ª
  • antigen excess
    Ç׿ø°úÀ×
  • antigen excess zone
    Ç׿ø°úÀ×±¸¿ª
  • base excess
    ¿°±â°úÀ×
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • accommodative excess
    Á¶Àý°ú´Ù
  • antibody excess
    Ç×ü°úÀ×(ù÷ô÷Φí¥).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antigen excess
    Ç׿ø°ú´Ù(ù÷ê«Î¦Òý).
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • antigen excess zone
    Ç׿ø°úÀ×´ë.
  • ADC (apparent diffusion coefficient)
    °Ñº¸±â È®»ê °è¼ö
  • apparent
    ¿Ü°ßÀû(èâúæîÜ), °Ñº¸±âÀÇ.
  • apparent
    ¿Ü°ßÀû(ËíÌ´Ëø), °Ñº¸±âÀÇ.
  • apparent anemia
    ¿Ü°ßÀû ºóÇ÷(¡­Þ¸úì).
  • apparent death
    °¡»ç(Ê£ÞÝ).
  • apparent density
    °Ñº¸±â ¹Ðµµ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • mineralocorticoid
    ÀüÇØÁú<¿°·ù>ÄÚ¸£Æ¼ÄÚÀ̵å
  • mineralocorticoid
    ÀüÇØÁú(¿°·ù)ºÎ½ÅÇÇÁúÈ£¸£¸ó
  • mineralocorticoid
    ±¤ÁúÄÚ¸£Æ¼ÄÚÀ̵å
  • mineralocorticoid
    ÀüÇØÁú<¿°·ù, ±¤Áú>ºÎ½ÅÇÇÁúÈ£¸£¸ó<ÄÚ¸£Æ¼ÄÚÀ̵å>.
  • mineralocorticoid stimulating test
    ±¤ÁúÄÚ¸£ ƼÄÚÀ̵åÀڱؽÃÇè(ÎÎòõ¡­ô§Ð½ãËúÐ).
  • apparent
    ¿Ü°ßÀû(èâúæîÜ), °Ñº¸±âÀÇ.
  • apparent
    ¿Ü°ßÀû(ËíÌ´Ëø), °Ñº¸±âÀÇ.
  • apparent anemia
    ¿Ü°ßÀû ºóÇ÷(¡­Þ¸úì).
  • apparent death
    °¡»ç(Ê£ÞÝ).
  • apparent density
    °Ñº¸±â ¹Ðµµ.
  • apparent diffusion coefficient (ADC)
    °Ñº¸±â È®»ê °è¼ö
  • apparent infection
    Çö¼º°¨¿°
  • apparent movement
    ½Ã¿îµ¿.
  • apparent strabismus
    ¿Ü°üÀû»ç½Ã(Ê£àõÞØãÊ).
  • apparent viscosity
    °Ñº¸±â Á¡¼º(µµ) (¡­ïÄàõöô).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Metabolic defect of steroid (Adrenogenital syndrome)
    ½ºÅ×·ÎÀ̵å´ë»ç°áÇÔ(ºÎ½Å»ý½Ä±âÁõÈıº)
    [¿¾ ¿ë¾î] ½ºÅ×·ÎÀ̵å´ë»ç°áÇÔ(ºÎ½Å»ý½Ä±âÁõÈıº)
  • Syndrome
    ÁõÈıº
    [¿¾ ¿ë¾î] ÁõÈÄ
  • Syndrome (Down)
    ÁõÈıº (´Ù¿îÁõÈıº)
    [¿¾ ¿ë¾î] ÁõÈÄ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Loeffler's syndrome
    ·ÚÇ÷¯ÁõÈıº
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • apparent specific volume
    ¿Ü°ß(èâ̸) ºñ(Ýï)¿ëÀû(é»îÝ)
  • mineralocorticoid
    ±¤Áú(ÎÎòõ)ÄÚ¸£Æ¼ÄÚÀ̵å
  • mineralocorticoid receptor
    ±¤Áú(ÎÎòõ) ÄÚ¸£Æ¼ÄÚÀÌµå ¼ö¿ëü(áôé»ô÷)
  • antibody-excess zone
    Ç×ü°úÀ×±¸¿ª(ù÷ô÷Φí¥Ï¡æ´)
  • antigen-excess zone
    Ç׿ø°úÀ× ±¸¿ª(ù÷ê«Î¦í¥Ï¡æ´)
  • atomic percent excess
    °ú´Ù ¿øÀÚ¹éºÐÀ²(ΦÒýê«í­ÛÝÝÂëÒ)
  • primary alkali excess
    ¿ø¹ß¼º(ê«Û¡àõ) ¾ËÄ®¸®°úÀ×(Φí¥)
  • primary carbon dioxide excess
    ¿ø¹ß¼º ÀÌ»êȭź¼Ò(ê´Û¡àõ ì£ß«ûù÷©áÈ) °úÀ×(Φí¥)
  • Crigler-Najjar syndrome
    Å©¸®±Û·¯-³ª¾ß¸£ ÁõÈıº(ñøý¦ÏØ)
  • Down's syndrome
    ´Ù¿î ÁõÈıº(ñøý¦ÏØ) (ÔÒ) mongolism
  • ectopic hormone syndrome
    À̼Ò(ì¶á¶) È£¸£¸ó ÁõÈıº(ñøý¦ÏØ)
  • Fanconi's syndrome
    ÆÇÄÚ´Ï ÁõÈıº(ñøý¦ÏØ)
  • fragile X syndrome
    Ãë¾à(öªå°) X ÁõÈıº(ñøý¦ÏØ)
  • general adaptation syndrome
    ÀÏ¹Ý ÀûÀÀ ÁõÈıº(ìéÚõ îêëëñøý¦ÏØ)
  • Hunter's syndrome
    ÇåÅÍ ÁõÈıº(ñøý¦ÏØ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • excess
    °úÀ×, À׿©
  • ADC [=apparent diffusion coefficient]
    °Ñº¸±âÈ®»ê°è¼ö
  • apparent
    ¸í¹éÇÑ, ¿Ü°ß»óÀÇ, °Íº¸±â
  • apparent diffusion coefficient [=ADC]
    °Ñº¸±âÈ®»ê°è¼ö
  • Banti's syndrome
    ¹ÝƼÁõÈıº
  • battered child syndrome
    ÇÇÇÐ´ë¾ÆÁõÈıº
  • Behcet's syndrome
    º£Ã¼Æ®ÁõÈıº
  • blind loop syndrome
    ¸Í°èÁ¦ÁõÈıº
  • cauda equina syndrome
    ¸¶¹ÌÁõÈıº
  • cord compression syndrome
    ô¼ö¾Ð¹ÚÁõÈıº
  • Cushing's syndrome
    Äí½ÌÁõÈıº
  • double crush syndrome
    ÀÌÁߺмâÁõÈıº
  • empty sella syndrome
    °øÅÍŰ¾ÈÁõÈıº
  • facet syndrome
    ôÃßÈİüÀýÁõÈıº
  • fetal distress syndrome
    žưï¶õÁõÈıº
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AME amphotericin methyl ester; apparent minerallocorticoid excess; aseptic meningoencephalitis
MC mass casualties; mast cell; Master of Surgery [Lat. Magister Chirurgiae]; maximum concentration; Med...
M-C mineralocorticoid
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
MS Maffuci syndrome; maladjustment score; mandibular series; Marfan syndrome; Marie-Strumpell [syndrome...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AME Apparent Mineralocorticoid Excess
MC Mineralocorticoid
MR Mineralocorticoid
MR Mineralocorticoid receptor
hMR human mineralocorticoid receptor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • mineralocorticoid exess syndrome
    ¿°·ù ÄÚ¸£Æ¼ÄÚÀ̵å Áõ´ÙÁõ
  • apparent diffusion coefficient
    °Ñº¸±â È®»ê °è¼ö
  • mineralocorticoid
    ¿°·ù ÄÚ¸£Æ¼ÄÚÀ̵å
    ½Å ¼¼´¢°üÀÇ »óÇÇ ¼¼Æ÷ ³»¿¡¼­ÀÇ À̿ ¼ö¼Û¿¡ ´ëÇÑ ÀÛ¿ëÀ» ÅëÇÑ ÀüÇØÁú ¹× ¼öºÐ ÆòÇü Á¶Àý¿¡ °ü¿©ÇÏ´Â ÄÚ¸£Æ¼ÄÚ ½ºÅ×·ÎÀ̵å, ÁÖ·Î ¾Ëµµ½ºÅ×·ÐÀ» ¸»ÇÏ¸ç ³ªÆ®·ýÀÇ Àú·ù¿Í Ä®·ýÀÇ »ó½ÇÀ» ÀÏÀ¸Å²´Ù. ¾î¶² °ÍÀº ¶ÇÇÑ ¿©·¯ °¡Áö Á¤µµÀÇ ´çÁú ÄÚ¸£Æ¼ÄÚÀ̵å ÀÛ¿ëµµ °®°í ÀÖ´Ù.
  • antibody excess zone
    Ç×ü °úÀ׿ª
  • antigen excess
    Ç׿ø °úÀ×
    ħ°­ ¹ÝÀÀ µî ÃÖÀûºñ¿¡¼­ ¹ÝÀÀÀÌ Àß °üÂûµÇ´Â °æ¿ì Ç׿øÀÇ ¾çÀÌ Áö³ªÄ¡°Ô ¸¹À¸¸é ¹Ý´ë·Î ¹ÝÀÀÀÌ ¾àÇØÁö°í °üÂûÀÌ °¡´ÉÇÑ ¹ÝÀÀÀÌ »ý±æ ¶§±îÁöÀÇ ½Ã°£ÀÌ ±æ¾îÁø´Ù. ÀÌ¿Í °°ÀÌ Ç׿øÀÌ °úÀ×µÇ¾î ¹ÝÀÀÀÌ °üÂûµÇÁö ¾Ê°Ô µÇ´Â °æ¿ì Ç׿ø °úÀ׿¡ ÀÇÇÑ ¹ÝÀÀÀÇ ¾ïÁ¦Çϰí ÇÑ´Ù. Ç׿ø Ç×ü º¹ÇÕü´Â Ç׿ø °úÀ×ÀÎ °æ¿ì¿¡´Â °¡¿ë¼ºÀÌ µÈ´Ù.
  • creatinaemia : excess of creatine in the blood.

    creatine kinase

    Å©·¹¾ÆÆ¾ Ű³ª¾ÆÁ¦
  • excess
    °úÀ×, À׿©
  • excess chlorine
    °úÀ× ¿°¼Ò
  • excess factor
    °úÀ× ÀÎÀÚ
  • excess lactate
    °úÀ× À¯»ê, °úÀ× À¯»ê¿°
  • excess sludge
    °úÀ× ½½·¯Áö
  • excess water
    À׿© ¼öºÐ
  • zone of antigen excess
    Ç׿ø °úÀ×´ë
    ºñ±³Àû °í³óµµÀÇ Ç׿ø´ë·Î¼­ ħ°­¹ÝÀÀ¿¡¼­ °¡¿ë¼º º¹ÇÕü°¡ Çü¼ºµÇ¸ç ¹ÝÀÀÀÌ ¾ïÁ¦µÈ´Ù.
  • A-V syndrome
    A-V ÁõÈıº
  • Aarskog syndrome
    ¾Æ¸£½ºÄÚ±× ÁõÈıº
    À¯Àü¼º ÁõÈıºÀÇ Çϳª·Î X-¿¬°ü¼º ÇüÁú·Î À¯ÀüµÈ´Ù. Ư¡À¸·Î´Â ¾È±¸ °Ý¸®Áõ, ³ÐÀº À­ ÀÔ¼ú, ¼î¿Ã, ÀÛÀº ¼Õ µîÀÌ ÀÖ´Ù. ¾È¸é ¼º±â Çü¼º Àå¾Ö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
apparent 1. Manifest; obvious; evident; e.g., a clinically apparent infection.
2. Frequently used (confusingly) to mean "seeming to be," ostensible, pseudo-.
Origin: L. Apparens, visible, fr. Appareo, to come in sight
(05 Mar 2000)
apparent viscosity <physiology> This refers to the ratio of shear stress to shear rate in a fluid, this ratio is dependent on the rate of shear.
(09 Oct 1997)
receptors, mineralocorticoid Cytoplasmic proteins that specifically bind mineralocorticoids and mediate their cellular effects. The receptor with its bound ligand acts in the nucleus to induce transcription of specific segments of DNA. Mineralocorticoids were named for their actions on extracellular electrolyte concentrations. The most important example is aldosterone.
(12 Dec 1998)
mineralocorticoid 1. <biochemistry> Any of the group of C21 corticosteroids, principally aldosterone, predominantly involved in the regulation of electrolyte and water balance through their effect on ion transport in epithelial cells of the renal tubules, resulting in retention of sodium and loss of potassium, some also possess varying degrees of glucocorticoid activity.
Their secretion is regulated principally by plasma volume, serum potassium concentration and angiotensin II and to a lesser extent by anterior pituitary ACTH.
2. <pharmacology> Of, pertaining to, having the properties of or resembling a mineralocorticoid.
(12 Jan 1998)
hormone, mineralocorticoid A group of hormones, the most important being aldosterone, that regulate the balance of water and electrolytes (ions such as sodium and potassium) in the body. The mineralocorticoid hormones act specifically on the tubules of the kidney.
(12 Dec 1998)
anaemia, refractory, with excess of blasts Chronic refractory anaemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
(12 Dec 1998)
antibody excess In a precipitation test, the presence of antibody in an amount greater than that required to combine with all of the antigen present.
(05 Mar 2000)
antigen excess In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases.
(05 Mar 2000)
base excess A measure of metabolic alkalosis, usually predicted from the Siggaard-Andersen nomogram; the amount of strong acid that would have to be added per unit volume of whole blood to titrate it to pH 7.4 while at 37°C and at a carbon dioxide pressure of 40 mm Hg.
(05 Mar 2000)
calcium excess Overly high intake of calcium (hypercalcaemia) may cause muscle weakness and constipation, affect the conduction of electrical impulses in the heart (heart block) lead to calcium stones in the urinary tract, impair kidney function (through nephrocalcinosis), and interfere with the absorption of iron predisposing to iron deficiency. According to the National Academy of Sciences, adequate intake of calcium is 1 gram daily for both men and women. The upper limit for calcium intake is 2.5 grams daily.
(12 Dec 1998)
magnesium excess Persons with impaired kidney function should be especially careful about their magnesium intake because they can accumulate magnesium, a dangerous situation. According to the national academy of sciences, the recommended dietary allowances of magnesium are 420 milligrams per day for men and 320 milligrams per day for women. The upper limit of magnesium as supplements is 350 milligrams daily, in addition to the magnesium from food and water.
(12 Dec 1998)
refractory anaemia with excess blasts <haematology> A form of myelodysplasia characterised by the build up of immature white blood cells (blasts) in the bone marrow.
If the immature cells are particularly numerous it may indicate a chance of transformation to acute leukaemia and the condition is called refractory anaemia with excess blasts in transformation (RAEBt).
Acronym: RAEB
(13 Nov 1997)
convergence excess That condition in which an oesophoria or esotropia is greater for near vision than for far vision.
(05 Mar 2000)
selenium excess Too much of the mineral selenium may cause reversible changes in the hair (balding) and nails, garlic odour to the breath, intestinal distress, weakness and slower mentation (slowed mental functionning). According to the national academy of sciences, the recommended dietary allowances of selenium are 70 milligrams per day for men and 55 milligrams per day for women.
(12 Dec 1998)
negative base excess A measure of metabolic acidosis, usually predicted from the Siggaard-Andersen nomogram; the amount of strong alkali that would have to be added per unit volume of whole blood to titrate it to pH 7.4 while at 37°C and at a carbon dioxide pressure of 40 mm Hg.
(05 Mar 2000)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Mineralocorticoid Excess Syndrome, Apparent - »õâ A hereditary disease characterized by childhood onset HYPERTENSION, hypokalemic alkalosis, and low RENIN and ALDOSTERONE secretion. It results from a defect in the activity of the 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2 enzyme which results in inadequate conversion of CORTISOL to CORTISONE. The build up of unprocessed cortisol to levels that stimulate MINERALOCORTICOID RECEPTORS creates the appearance of having excessive MINERALOCORTICOIDS.
    Synonyms :
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • apparent
    ´«¿¡ º¸ÀÌ´Â
  • apparent
    ¸í¹éÇÑ;º¸ÀÌ´Â;¿Ü°ßÀÇ;°ÅÁ׸¸ÀÇ;°Ñ²Ù¹ÒÀÇ
  • apparent time
    (ÇØ½Ã°èµîÀÇ)žçÀÇ À§Ä¡·Î ÃøÁ¤Çϴ½ð£
  • heir apparent
    ¹ýÁ¤ ÃßÁ¤ »ó¼ÓÀÎ
  • excess
    °ú´Ù(ÀÇ); ÆøÀ½(½Ä)
  • excess
    °úµµ;°ú´Ù;°úÀ×;Ãʰú;Ãʰú·®;ºÎÀýÁ¦;Áö³ªÄ§;³­Æø;ÆøÀ½Æø½Ä(excess of imports over exports ¼öÀÔ Ãʰú) a
  • excess baggage
    Á¦ÇÑ Ãʰú ¼öÇϹ°
  • excess charge
    ÁÖÂ÷ ½Ã°£ Ãʰú ¿ä±Ý
  • excess fare
    öµµÀÇ °Å¸® Ãʰú ¿ä±Ý;Ãʰú ¿ä±Ý
  • excess luggage
    =EXCESS BAGGAGE
  • excess postage
    ¿ìÇ¥ ºÎÁ· ¿ä±Ý
  • excess reserves
    (ÀºÇà)Ãʰú Áغñ±Ý
  • excess supply
    (°æ)°ø±Þ Ãʰú(°úÀ×)
  • Down's syndrome
    ´Ù¿î ÁõÈıº(Mongolism)
  • HunterRussel syndrome
    ÇåÅÍ ·¯¼¿ ÁõÈıº(À¯±â ¼öÀº Áßµ¶)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á